

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 8.0      Revision Date: 2024/04/06      SDS Number: 23082-00024      Date of last issue: 2023/09/26  
Date of first issue: 2014/10/17

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Montelukast Tablet Formulation

#### Supplier's company name, address and phone number

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

E-mail address : EHSSTEWARD@organon.com

Emergency telephone number : +1-215-631-6999

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### GHS classification of chemical product

Not a hazardous substance or mixture according to the Globally Harmonised System (GHS).

#### GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

#### Other hazards which do not result in classification

Important symptoms and outlines of the emergency assumed : Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

---

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Cellulose	9004-34-6	$\geq 30 - < 40$	
Montelukast	151767-02-1	$\geq 1 - < 10$	
Magnesium stearate	557-04-0	$> 0 - < 10$	2-611

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 8.0      Revision Date: 2024/04/06      SDS Number: 23082-00024      Date of last issue: 2023/09/26  
Date of first issue: 2014/10/17

Titanium dioxide	13463-67-7	> 0 - < 10	1-558, 5-5225
------------------	------------	------------	---------------

### 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

## 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 7. HANDLING AND STORAGE

### Handling

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
8.0	2024/04/06	23082-00024	2023/09/26
			Date of first issue: 2014/10/17

flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Storage**

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Reference concentration / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Montelukast	151767-02-1	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH
Titanium dioxide	13463-67-7	OEL-M (Respirable particulate matter)	1.5 mg/m <sup>3</sup> (Titanium)	JP OEL JSOH
	Further information: Group 2B: possibly carcinogenic to humans			
		OEL-M (Total particulate matter)	2 mg/m <sup>3</sup> (Titanium)	JP OEL JSOH
	Further information: Group 2B: possibly carcinogenic to humans			

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

**Personal protective equipment**

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

Physical state	:	tablet
Colour	:	coloured
Odour	:	odourless
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Boiling point, initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Lower explosion limit and upper explosion limit / flammability limit	:	
Upper explosion limit / Upper explosion limit / Lower explosion limit / per flammability limit	:	No data available

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Decomposition temperature	:	No data available
pH	:	No data available
Evaporation rate	:	No data available
Auto-ignition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n- octanol/water	:	No data available
Vapour pressure	:	No data available
Density and / or relative density Relative density	:	No data available
Density	:	No data available
Relative vapour density	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	No data available

---

### 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

Incompatible materials : Oxidizing agents  
 Hazardous decomposition products : No hazardous decomposition products are known.

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
 Skin contact  
 Ingestion  
 Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
 Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
 Exposure time: 4 h  
 Test atmosphere: dust/mist  
 Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Montelukast:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
 LD50 (Mouse): > 5,000 mg/kg  
 Acute inhalation toxicity : Remarks: No data available  
 Acute dermal toxicity : Remarks: No data available

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
 Method: OECD Test Guideline 423  
 Assessment: The substance or mixture has no acute oral toxicity  
 Remarks: Based on data from similar materials  
 Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
 Remarks: Based on data from similar materials

**Titanium dioxide:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
 Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l  
 Exposure time: 4 h  
 Test atmosphere: dust/mist

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

Assessment: The substance or mixture has no acute inhalation toxicity

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Montelukast:**

Species	: Rabbit
Result	: Mild skin irritation

**Magnesium stearate:**

Species	: Rabbit
Result	: No skin irritation
Remarks	: Based on data from similar materials

**Titanium dioxide:**

Species	: Rabbit
Result	: No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Montelukast:**

Species	: Rabbit
Result	: Severe irritation

**Magnesium stearate:**

Species	: Rabbit
Result	: No eye irritation
Remarks	: Based on data from similar materials

**Titanium dioxide:**

Species	: Rabbit
Result	: No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.



## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

**Components:****Montelukast:**

Remarks : No data available

**Magnesium stearate:**

Test Type : Maximisation Test  
 Exposure routes : Skin contact  
 Species : Guinea pig  
 Method : OECD Test Guideline 406  
 Result : negative  
 Remarks : Based on data from similar materials

**Titanium dioxide:**

Test Type : Local lymph node assay (LLNA)  
 Exposure routes : Skin contact  
 Species : Mouse  
 Result : negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Test Type: In vitro mammalian cell gene mutation test  
 Result: negative  
 Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
 Species: Mouse  
 Application Route: Ingestion  
 Result: negative

**Montelukast:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Test Type: In vitro mammalian cell gene mutation test  
 Test system: Chinese hamster fibroblasts  
 Result: negative  
 Test Type: Chromosomal aberration  
 Test system: Chinese hamster ovary cells  
 Result: negative  
 Test Type: Alkaline elution assay

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

Test system: rat hepatocytes  
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Titanium dioxide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**Montelukast:**

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Mouse  
Application Route : Oral

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

Exposure time	: 92 weeks
Result	: negative

**Titanium dioxide:**

Species	: Rat
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 2 Years
Method	: OECD Test Guideline 453
Result	: positive
Remarks	: The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment	: Limited evidence of carcinogenicity in inhalation studies with animals.
------------------------------	---

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

**Montelukast:**

Effects on fertility	: Test Type: Fertility Species: Rat, male Application Route: Oral Fertility: NOAEL: 800 mg/kg body weight Result: Animal testing did not show any effects on fertility.
	Test Type: Fertility Species: Rat, female Application Route: Oral Fertility: LOAEL: 200 mg/kg body weight Symptoms: Reduced fertility
	Test Type: Fertility Species: Rat, female Application Route: Oral Fertility: NOAEL: 100 mg/kg body weight Symptoms: Reduced fertility

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

**Magnesium stearate:**

Effects on fertility	:	Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Cellulose:**

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

**Montelukast:**

Species	:	Monkey, male and female
NOAEL	:	150 - 300 mg/kg
Application Route	:	Oral
Exposure time	:	53 Weeks
Remarks	:	No significant adverse effects were reported

Species	:	Rat
NOAEL	:	50 mg/kg
Application Route	:	Oral
Exposure time	:	53 Weeks
Remarks	:	No significant adverse effects were reported

Species	:	Mouse
NOAEL	:	50 mg/kg
Application Route	:	Oral
Exposure time	:	14 Weeks
Remarks	:	No significant adverse effects were reported

**Magnesium stearate:**

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

**Titanium dioxide:**

Species	: Rat
NOAEL	: 24,000 mg/kg
Application Route	: Ingestion
Exposure time	: 28 Days

Species	: Rat
NOAEL	: 10 mg/m <sup>3</sup>
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 2 yr

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Montelukast:**

Skin contact	: Remarks: May irritate skin.
Eye contact	: Symptoms: Severe irritation
Ingestion	: Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhoea, Fever

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--

**Montelukast:**

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other	: EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

aquatic invertebrates		Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility
		NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.23 mg/l Exposure time: 21 d Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	:	EC50: > 100 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility

**Magnesium stearate:**

Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

	<p>Test substance: Water Accommodated Fraction  Method: OECD Test Guideline 201  Remarks: Based on data from similar materials  No toxicity at the limit of solubility</p> <p>NOELR (Pseudokirchneriella subcapitata (green algae)): &gt; 1 mg/l  Exposure time: 72 h  Test substance: Water Accommodated Fraction  Method: OECD Test Guideline 201  Remarks: Based on data from similar materials</p>
Toxicity to microorganisms	: EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

**Titanium dioxide:**

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l Exposure time: 72 h
Toxicity to microorganisms	: EC50: > 1,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Cellulose:**

Biodegradability	: Result: Readily biodegradable.
------------------	----------------------------------

**Montelukast:**

Biodegradability	: Result: not rapidly degradable Biodegradation: 0 % Exposure time: 28 d
------------------	--

Stability in water	: Hydrolysis: 50 %(21.7 h)
--------------------	----------------------------

**Magnesium stearate:**

Biodegradability	: Result: Not biodegradable Remarks: Based on data from similar materials
------------------	--

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

**Bioaccumulative potential****Components:****Montelukast:**

Partition coefficient: n-octanol/water	:	log Pow: > 4.3
--	---	----------------

**Magnesium stearate:**

Partition coefficient: n-octanol/water	:	log Pow: > 4
--	---	--------------

**Mobility in soil**

No data available

**Hazardous to the ozone layer**

Not applicable

**Other adverse effects**

No data available

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	:	Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

**IATA-DGR**

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable



# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 8.0      Revision Date: 2024/04/06      SDS Number: 23082-00024      Date of last issue: 2023/09/26  
Date of first issue: 2014/10/17

ger aircraft)

### IMDG-Code

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

Refer to section 15 for specific national regulation.

### Special precautions for user

Not applicable

## 15. REGULATORY INFORMATION

### Related Regulations

#### Fire Service Law

Not applicable to dangerous materials / designated flammables.

#### Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

#### Industrial Safety and Health Law

#### Harmful Substances Prohibited from Manufacture

Not applicable

#### Harmful Substances Required Permission for Manufacture

Not applicable

#### Substances Prevented From Impairment of Health

Not applicable

#### Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

#### Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

#### Substances Subject to be Notified Names

Article 57-2 (Enforcement Order Table 9)

Chemical name	Concentration (%)	Remarks
Magnesium stearate	>0 - <10	-

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 8.0      Revision Date: 2024/04/06      SDS Number: 23082-00024      Date of last issue: 2023/09/26  
Date of first issue: 2014/10/17

Titanium(IV) oxide	>0 - <10	-
--------------------	----------	---

### Substances Subject to be Indicated Names

Article 57 (Enforcement Order Article 18)

Chemical name	Remarks
Magnesium stearate	-

### Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

### Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

### Ordinance on Prevention of Lead Poisoning

Not applicable

### Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

### Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

### Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

### Poisonous and Deleterious Substances Control Law

Not applicable

### Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

### High Pressure Gas Safety Act

Not applicable

### Explosive Control Law

Not applicable

### Vessel Safety Law

Not regulated as a dangerous good

### Aviation Law

Not regulated as a dangerous good

### Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

### Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

**Waste Disposal and Public Cleansing Law**

Industrial waste

**The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

---

**16. OTHER INFORMATION**

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
JP OEL JSOH	:	Japan. The Japan Society for Occupational Health. Recommendation of Occupational Exposure Limits
ACGIH / TWA	:	8-hour, time-weighted average
JP OEL JSOH / OEL-M	:	Occupational Exposure Limit-Mean

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
8.0	2024/04/06	23082-00024	Date of first issue: 2014/10/17

---

Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN